Skip to main content
The potential clinical application of protein kinase C beta II peptide inhibitor or Gö 6983 in vascular endothelial dysfunction
Current Topics in Pharmacology
  • Qian Chen
  • Brian Rueter
  • Samuel Krass
  • Christopher Zambrano
  • Shawn Thomas
  • Catherine Prince
  • Brandon Bell
  • Vincent Chai
  • Jeffery Emrich
  • Lindon Young, Philadelphia College of Osteopathic Medicine
Document Type
Publication Date
Vascular endothelial dysfunction which is associated with increased oxidative stress and decreased endothelial-derived nitric oxide has been considered as a major initial event in various diseases, such as atherosclerosis, diabetes and ischemia/reperfusion (I/R) injury. Previously we found that a broad-spectrum protein kinase C (PKC) inhibitor (i.e., Gö 6983) and a specific PKC beta II peptide inhibitor (PKC ßII-) were cardioprotective in myocardial I/R injury. However, the direct effects of Gö6983 or PKC ßII- on vascular endothelial dysfunction and the related leukocyte-endothelial interactions are still unclear. The leukocyte rolling, adherence and transmigration were estimated by using intravital microscopy in rat mesenteric postcapillary venules. We found that superfusion of NG -nitro-L-arginine-methyl-ester (L-NAME, 50 µM) induced endothelial dysfunction and significantly increased leukocyte-endothelial interactions within a 2 hour period compared to Krebs' buffer control group (P<0.05). By contrast, Gö6983 (25 nM-200 nM) or PKC ßII- (0.1 µM-10 µM) dose-dependently attenuated these interactions induced by L-NAME (P<0.05). Moreover, histological evaluation of Gö 6983 (200 nM) or PKC ßII- (10 µM) superfused mesenteric tissue exhibited significantly less leukocyte adherence and tissue transmigration, as well as significantly less intercellular adhesion molecule-1 expression compared to L-NAME group. Finally, in a rat extracorporeal shock wave lithotripsy model, we demonstrated that PKC ßII- (0.055-0.55 mg/kg) significantly decreased oxidative stress when hydrogen peroxide was measured directly from rat renal veins (P<0.05). In summary, Gö 6983 or PKC ßII- can decrease the proinflammatory responses in vascular endothelium and may provide a potential clinical treatment to prevent vascular endothelial dysfunction.

This article was published in Current Topics in Pharmacology, Volume 14, Issue 42006, Pages 11-24.

The published version is available at .

Copyright © 2010 Research Trends.

Citation Information
Qian Chen, Brian Rueter, Samuel Krass, Christopher Zambrano, et al.. "The potential clinical application of protein kinase C beta II peptide inhibitor or Gö 6983 in vascular endothelial dysfunction" Current Topics in Pharmacology Vol. 14 Iss. 42006 (2010) p. 11 - 24
Available at: